PURPOSE: In the American Joint Committee on Cancer 2010 classification system, pT1-2N0 oral cavity squamous cell carcinoma (OSCC) is considered an early-stage cancer treatable with surgery alone (National Comprehensive Cancer Network 2010 guidelines). Our aim was to evaluate the feasibility of surgery alone for pT1-2N0 OSCC patients. METHODS AND MATERIALS: Among 1279 previously untreated OSCC patients referred to our hospital between January 1996 and May 2008, we identified 457 consecutive patients with pT1-2N0 disease. All had radical tumor excision with neck dissection. A total of 387 patients showing pathologic margins greater than 4 mm and treated by surgery alone were included in the final analysis. All were followed up for at least 24 months after surgery or until death. The 5-year rates of control, distant metastasis, and survival were the main outcome measures. RESULTS: The 5-year rates in the entire group of pT1-2N0 patients were as follows: local control, 91%; neck control, 92%; distant metastases, 1%; disease-free survival, 85%; disease-specific survival, 93%; and overall survival, 84%. Multivariate analysis identified poor differentiation and pathologic tumor depth of 4 mm or greater as independent risk factors for neck control, disease-free survival, and disease-specific survival. A scoring system using poor differentiation and tumor depth was formulated to define distinct prognostic groups. The presence of both poorly differentiated tumors and a tumor depth of 4 mm or greater resulted in significantly poorer 5-year neck control (p < 0.0001), disease-free (p < 0.0001), disease-specific (p < 0.0001), and overall survival (p = 0.0046) rates. CONCLUSION: The combination of poor differentiation and pathologic tumor depth of 4 mm or greater identified a subset of pT1-2N0 OSCC patients with poor outcome, who may have clinical benefit from postoperative adjuvant radiotherapy.
PURPOSE: In the American Joint Committee on Cancer 2010 classification system, pT1-2N0 oral cavity squamous cell carcinoma (OSCC) is considered an early-stage cancer treatable with surgery alone (National Comprehensive Cancer Network 2010 guidelines). Our aim was to evaluate the feasibility of surgery alone for pT1-2N0 OSCC patients. METHODS AND MATERIALS: Among 1279 previously untreated OSCC patients referred to our hospital between January 1996 and May 2008, we identified 457 consecutive patients with pT1-2N0 disease. All had radical tumor excision with neck dissection. A total of 387 patients showing pathologic margins greater than 4 mm and treated by surgery alone were included in the final analysis. All were followed up for at least 24 months after surgery or until death. The 5-year rates of control, distant metastasis, and survival were the main outcome measures. RESULTS: The 5-year rates in the entire group of pT1-2N0 patients were as follows: local control, 91%; neck control, 92%; distant metastases, 1%; disease-free survival, 85%; disease-specific survival, 93%; and overall survival, 84%. Multivariate analysis identified poor differentiation and pathologic tumor depth of 4 mm or greater as independent risk factors for neck control, disease-free survival, and disease-specific survival. A scoring system using poor differentiation and tumor depth was formulated to define distinct prognostic groups. The presence of both poorly differentiated tumors and a tumor depth of 4 mm or greater resulted in significantly poorer 5-year neck control (p < 0.0001), disease-free (p < 0.0001), disease-specific (p < 0.0001), and overall survival (p = 0.0046) rates. CONCLUSION: The combination of poor differentiation and pathologic tumor depth of 4 mm or greater identified a subset of pT1-2N0 OSCC patients with poor outcome, who may have clinical benefit from postoperative adjuvant radiotherapy.
Authors: Ardalan Ebrahimi; Ziv Gil; Moran Amit; Tzu-Chen Yen; Chun-Ta Liao; Pankaj Chaturvedi; Jai Prakash Agarwal; Luiz P Kowalski; Hugo F Köhler; Matthias Kreppel; Claudio R Cernea; Jason Brandao; Gideon Bachar; Andrea Bolzoni Villaret; Dan M Fliss; Eran Fridman; Kevin Thomas Robbins; Jatin P Shah; Snehal G Patel; Jonathan R Clark Journal: Head Neck Date: 2019-02-24 Impact factor: 3.147
Authors: Darragh S Gogarty; Paul Lennon; Sandra Deady; J Barry O'Sullivan; Orla McArdle; Mary Leader; Patrick Sheahan; James Paul O'Neill Journal: Eur Arch Otorhinolaryngol Date: 2016-08-23 Impact factor: 2.503
Authors: Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Steven B Chinn; Matthew E Spector; Emily L Bellile; Jonathan B McHugh; Thomas J Gernon; Carol R Bradford; Gregory T Wolf; Avraham Eisbruch; Douglas B Chepeha Journal: Otolaryngol Head Neck Surg Date: 2013-10-23 Impact factor: 3.497
Authors: Mark W Kubik; Shaum Sridharan; Mark A Varvares; Dan P Zandberg; Heath D Skinner; Raja R Seethala; Simion I Chiosea Journal: Head Neck Pathol Date: 2020-03-02
Authors: Evangelia Katsoulakis; Jonathan E Leeman; Benjamin H Lok; Weiji Shi; Zhigang Zhang; Jillian C Tsai; Sean M McBride; Eric J Sherman; Marc Cohen; Richard Wong; Ian Ganly; Nancy Y Lee; Nadeem Riaz Journal: Laryngoscope Date: 2018-04-10 Impact factor: 3.325
Authors: Danielle N Margalit; Assuntina G Sacco; Jay S Cooper; John A Ridge; Richard L Bakst; Beth M Beadle; Jonathan J Beitler; Steven S Chang; Allen M Chen; Tom J Galloway; Shlomo A Koyfman; Carol Mita; Jared R Robbins; C Jillian Tsai; Minh T Truong; Sue S Yom; Farzan Siddiqui Journal: Head Neck Date: 2020-10-23 Impact factor: 3.147